TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27671459

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS) combined with GSV high ligation
Number of subjects: 177

Group type: COMPARATOR
Intervention: GSV stripping plus multistab avulsion or transilluminated powered phlebectomy (TIPP)
Number of subjects: 177
Study: 26330362

Group type: EXPERIMENTAL
Intervention: Tiopronin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no tiopronin)
Number of subjects: 82
Study: 23442286

Group type: EXPERIMENTAL
Intervention: Combined resisted agility and repeated sprint training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 20
Study: 21143465

Group type: EXPERIMENTAL
Intervention: Topical niacin pretreatment with 585-nm pulsed dye laser (PDL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 585-nm pulsed dye laser (PDL) without niacin pretreatment
Number of subjects: 18
Study: 18341678

Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 17
Study: 16492205

Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg) administered at -60 min relative to a standardized breakfast meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg) administered at -15 min relative to a standardized breakfast meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg) administered at 0 min relative to a standardized breakfast meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg) administered at +30 min relative to a standardized breakfast meal
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exenatide (10 microg) administered at +60 min relative to a standardized breakfast meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo administered at -15 min relative to a standardized breakfast meal
Number of subjects: 18
Study: 12559646

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11194596

Group type: COMPARATOR
Intervention: Heart rate variability analysis (time and frequency domain measures)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Electrophysiological study
Number of subjects: 25

Group type: COMPARATOR
Intervention: Heart rate variability analysis
Number of subjects: 25

Group type: COMPARATOR
Intervention: Correlation analysis of autonomic tone parameters and atrial vulnerability markers
Number of subjects: 25
Study: 8615351

Group type: EXPERIMENTAL
Intervention: Dietary linoleic acid intake
Number of subjects: 393
Study: 1362038

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of myofascial trigger points for 30 seconds
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 14
Study: 6379788

Group type: EXPERIMENTAL
Intervention: Fenoterol (0.2 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Salbutamol (0.4 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fenoterol (0.2 mg) and Salbutamol (0.4 mg)
Number of subjects: 20
Study: 31833799

Group type: EXPERIMENTAL
Intervention: PepCan HPV therapeutic vaccine
Number of subjects: 31
Study: 30003567

Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 1503

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1503

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1503
Study: 27021726

Group type: EXPERIMENTAL
Intervention: Reclaimed wastewater-irrigated produce
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresh water-irrigated produce
Number of subjects: 0
Study: 25406657

Group type: COMPARATOR
Intervention: Rifabutin 150 mg three times weekly (tiw)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rifabutin 150 mg daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rifabutin 300 mg daily
Number of subjects: 16
Study: 23080039

Group type: EXPERIMENTAL
Intervention: Assist-as-needed robot training
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional tabletop therapy
Number of subjects: 26
Study: 20212343

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients with detectable levels of Anti-CMV IgG antibodies
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched individuals)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients with anti-CMV IgM antibodies
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (blood donors)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients with detectable MCP-1 levels
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients with detectable IL-8 levels
Number of subjects: 150
Study: 18596311

Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine-supplemented parenteral nutrition (PN)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard parenteral nutrition (PN)
Number of subjects: 44
Study: 16048758

Group type: EXPERIMENTAL
Intervention: Clindamycin 1% gel once-a-day
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Clindamycin 1% solution twice-a-day
Number of subjects: 592

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 592
Study: 12587340

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 10356632

Group type: EXPERIMENTAL
Intervention: High dependence group
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Low dependence group
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 7746978

Group type: EXPERIMENTAL
Intervention: Four treatment regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian ideas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer simulation
Number of subjects: 0
Study: 1961956

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg, intravenously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium thiopental (5 mg/kg, intravenously)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium thiopental
Number of subjects: 20
Study: 7042481

Group type: EXPERIMENTAL
Intervention: Oral atenolol 25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral atenolol 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral atenolol 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30326244

Group type: EXPERIMENTAL
Intervention: Smartphone-based lifestyle intervention
Number of subjects: 60
Study: 30160061

Group type: EXPERIMENTAL
Intervention: Basic Plus (moderate intensity; counseling by primary care clinician and a lifestyle coach)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Basic (clinician counseling only)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Basic Plus
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Each additional coaching visit in Basic Plus
Number of subjects: 261
Study: 27861546

Group type: EXPERIMENTAL
Intervention: Intravenous nutrition (1000 ml/24 h, 700 kcal)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no intravenous nutrition)
Number of subjects: 100
Study: 25322311

Group type: EXPERIMENTAL
Intervention: Modified NIATx process improvement model with training in HIV services and coaching
Number of subjects: 14

Group type: COMPARATOR
Intervention: HIV training only (control group)
Number of subjects: 14
Study: 22483541

Group type: EXPERIMENTAL
Intervention: Below-elbow cast (BEC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Above-elbow cast (AEC)
Number of subjects: 66
Study: 20942286

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (at Hegu (LI 4), Waiguan (TE 5), Jinmen (BL 63), Taichong (LR 3), Zusanli (ST 36), Qiuxu (GB 40)) during anesthesia
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no electroacupuncture)
Number of subjects: 80
Study: 17906008

Group type: EXPERIMENTAL
Intervention: Low-dose E2/levonorgestrel (0.023 mg/d 17beta-estradiol and 0.0075 mg/d levonorgestrel)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Micro-dose E2 (0.014 mg/d 17beta-estradiol)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Micro-dose E2
Number of subjects: 425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study: 15772925

Group type: EXPERIMENTAL
Intervention: 2.27% glucose dialysis solution
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 3.86% glucose dialysis solution
Number of subjects: 23
Study: 11893366

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg administered daily for 6 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normolipidemic controls
Number of subjects: 18
Study: 9916601

Group type: COMPARATOR
Intervention: Sildenafil citrate 25 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sildenafil citrate 50 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sildenafil citrate 100 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 7842147

Group type: EXPERIMENTAL
Intervention: Nortriptyline hydrochloride prescribed by primary care physicians trained in clinical guidelines
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Continuation phase of treatment with antidepressant medication
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Antidepressant medication as per AHCPR guidelines
Number of subjects: 91
Study: 2221313

Group type: COMPARATOR
Intervention: Thiopentone 3‐6 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Propofol 1‐3 mg/kg mixed with lignocaine (10/200 mg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Propofol 1‐3 mg/kg followed by alfentanil 0.01 mg/kg
Number of subjects: 75
Study: 750185

Group type: EXPERIMENTAL
Intervention: 2 mg suppository
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 3 mg suppository
Number of subjects: 201
Study: 31740726

Group type: EXPERIMENTAL
Intervention: Active tDCS group
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 38
Study: 31290589

Group type: EXPERIMENTAL
Intervention: bleached for 45 min, treated with sodium ascorbate (SA) for 2 min, and bonded
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: bleached for 12 days, treated with SA for 10 min, and bonded
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: bleached for 45 min, bonded immediately
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: bleached for 12 days, bonded immediately
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: bleached for 45 min, bonded after 2 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: bleached for 12 days, bonded after 2 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: etch-and-rinse mode
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: self-etch mode
Number of subjects: 70

Group type: COMPARATOR
Intervention: control (unbleached)
Number of subjects: 70
Study: 29297555

Group type: EXPERIMENTAL
Intervention: 4% TiF4‐gel applied once (TiF41)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 4% TiF4‐gel applied twice (TiF42)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 4% TiF4‐gel applied three times (TiF43)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group subjected to 1 erosive/abrasive cycle (C1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group subjected to 2 erosive/abrasive cycles (C2)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group subjected to 3 erosive/abrasive cycles (C3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: In vitro uneroded samples (UN) subjected to 3 erosive/abrasive cycles
Number of subjects: 72
Study: 25929594

Group type: EXPERIMENTAL
Intervention: Eltrombopag 12.5 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose-titration regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed doses of eltrombopag (12.5, 25, 50, 75 mg once daily)
Number of subjects: 0
Study: 23259702

Group type: EXPERIMENTAL
Intervention: Post-teriparatide group (after 72 weeks of teriparatide injections)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Post-placebo group (after 72 weeks of placebo injections)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Bisphosphonates treatment after teriparatide
Number of subjects: 465
Study: 22256222

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) over the left primary motor cortex (M1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 19054188

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (1.7 g DHA and 0.6 g EPA per day)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo (0.6 g linoleic acid per day)
Number of subjects: 204
Study: 16702317

Group type: EXPERIMENTAL
Intervention: Carob fiber (0, 5, 10, or 20 g)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Carob fiber (20 g)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 20
Study: 14962718

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Number of subjects: 68

Group type: COMPARATOR
Intervention: FACIT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both questionnaires
Number of subjects: 68
Study: 11731509

Group type: EXPERIMENTAL
Intervention: Opioid analgesics prescribed on an around-the-clock (ATC) basis
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Opioid analgesics prescribed on an as-needed (PRN) basis
Number of subjects: 65
Study: 11027118

Group type: EXPERIMENTAL
Intervention: Videoconferencing (n = 76)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conventional hospital outpatient clinic (n = 69)
Number of subjects: 145
Study: 8990406

Group type: EXPERIMENTAL
Intervention: Reteplase (10 + 10 U double bolus)
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 930
Study: 1619382

Group type: EXPERIMENTAL
Intervention: Benazepril (20 mg daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg daily)
Number of subjects: 29
Study: 6390203

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 187

Group type: COMPARATOR
Intervention: Medical-regimen
Number of subjects: 187
Study: 30634657

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 103
Study: 30063280

Group type: EXPERIMENTAL
Intervention: Immediate-loaded mini dental implants
Number of subjects: 30

Group type: COMPARATOR
Intervention: Immediate-loaded conventional-size dental implants
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 26966971

Group type: COMPARATOR
Intervention: 1-level ACDF
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 2-level ACDF
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 186
Study: 24974075

Group type: COMPARATOR
Intervention: Prophylaxis (ondansetron 8mg at cord clamping)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Treatment (ondansetron 8mg as required)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (normal saline 4mL in both)
Number of subjects: 82
Study: 21843948

Group type: EXPERIMENTAL
Intervention: Biopex(®) group (40 sides)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (40 sides)
Number of subjects: 40
Study: 19962227

Group type: EXPERIMENTAL
Intervention: Degarelix 240 mg for 1 month, then 80 mg monthly
Number of subjects: 610

Group type: COMPARATOR
Intervention: Leuprolide 7.5 mg/month
Number of subjects: 610
Study: 17433027

Group type: EXPERIMENTAL
Intervention: Standard-dose lenograstim (263 microg/d)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Low-dose lenograstim (105 microg/d)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 16290957

Group type: EXPERIMENTAL
Intervention: Comprehensive cardiac rehabilitation (CR) - 6 weeks of intensive CR and 12 months of follow-up including patient education, exercise training, dietary counseling, smoking cessation, psychosocial support, risk factor management, and clinical assessment.
Number of subjects: 770

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 770
Study: 12079295

Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 16
Study: 9805346

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (325 mg on alternate days)
Number of subjects: 20979

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20979
Study: 7624987

Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg of ofloxacin
Number of subjects: 360

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 360
Study: 2239769

Group type: EXPERIMENTAL
Intervention: Medium-chain triglyceride (MCT) diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-chain triglyceride (LCT) diet
Number of subjects: 0
Study: 31511052

Group type: EXPERIMENTAL
Intervention: Dangling protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-dangling protocol
Number of subjects: 0
Study: 27377435

Group type: EXPERIMENTAL
Intervention: Bluetooth hearing aid device A
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bluetooth hearing aid device B
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bluetooth hearing aid device A and B
Number of subjects: 30
Study: 26289352

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg once daily for 6 months
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Matching placebo capsules for 6 months
Number of subjects: 6000
Study: 23807060

Group type: EXPERIMENTAL
Intervention: Black women Veterans
Number of subjects: 3611

Group type: EXPERIMENTAL
Intervention: Hispanic women Veterans
Number of subjects: 3611

Group type: COMPARATOR
Intervention: White women Veterans
Number of subjects: 3611
Study: 21570531

Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study: 19420019

Group type: EXPERIMENTAL
Intervention: fosamprenavir/atazanavir/ritonavir (Group 1)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: saquinavir/atazanavir/ritonavir (Group 2)
Number of subjects: 61
Study: 16397363

Group type: EXPERIMENTAL
Intervention: ED‐71 (vitamin D analog)
Number of subjects: 0
Study: 15075170

Group type: EXPERIMENTAL
Intervention: Replacement flued gas or electric heaters
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control (unflued gas heaters)
Number of subjects: 198
Study: 11157685

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 5974
Study: 9239449

Group type: EXPERIMENTAL
Intervention: Sublingual spray of 0.4 mg GTN (two puffs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sublingual tablet of 0.5 mg GTN
Number of subjects: 24
Study: 8421980

Group type: EXPERIMENTAL
Intervention: Nifedipine (administered to 20 patients: 8 in group 1, 12 in group 2)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Metoprolol (administered to 21 patients: 9 in group 1, 12 in group 2)
Number of subjects: 41
Study: 3334056

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg twice daily for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice daily and Acebutolol 200 mg twice daily in combination for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination treatment (Nifedipine and Acebutolol)
Number of subjects: 0
Study: 29285549

Group type: EXPERIMENTAL
Intervention: Abaloparatide-SC
Number of subjects: 1645

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1645
Study: 28558978

Group type: EXPERIMENTAL
Intervention: tofacitinib 5mg
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: tofacitinib 10mg
Number of subjects: 316

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 316
Study: 26607232

Group type: EXPERIMENTAL
Intervention: Workplace physical exercise (WORK) performed during working hours for 5x10 min per week and up to 5 group‐based coaching sessions on motivation for regular physical exercise
Number of subjects: 200

Group type: COMPARATOR
Intervention: Home‐based physical exercise (HOME) performed during leisure time for 5x10 min per week
Number of subjects: 200
Study: 24292111

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (arm A)
Number of subjects: 2106

Group type: COMPARATOR
Intervention: Axillary nodal irradiation (arm B)
Number of subjects: 2106
Study: 21041839

Group type: EXPERIMENTAL
Intervention: Dianicline
Number of subjects: 602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study: 18251757

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (Arnica montana 5 CH, Bryonia alba 5 CH, Hypericum perforatum 5 CH, Ruta graveolens 3 DH)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 158

Group type: COMPARATOR
Intervention: Open-label noninterventional control arm
Number of subjects: 158
Study: 16513246

Group type: EXPERIMENTAL
Intervention: Local estrogen treatment (25-mcg estradiol vaginal tablet or 1g conjugated estrogen cream intravaginally daily for 2 weeks, then twice a week for 10 weeks)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Local estrogen treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no hormone replacement therapy)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study: 12589396

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bupropion (100-200 mg/day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day) in 10 depressed patients
Number of subjects: 17
Study: 10826454

Group type: EXPERIMENTAL
Intervention: Ultrasound screening for AAA
Number of subjects: 52745
Study: 8854287

Group type: EXPERIMENTAL
Intervention: Silicol gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 30
Study: 1378156

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nifedipine 10 mg t.i.d.
Number of subjects: 20
Study: 6692648

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefoperazone (CFP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intravenous cefoperazone (CFP)
Number of subjects: 7